TEV 56278
Alternative Names: TEV-56278Latest Information Update: 29 Jul 2024
At a glance
- Originator Teva Pharmaceutical Industries
- Class Antineoplastics
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 11 Jul 2024 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater, Combination therapy) in USA (IV) (NCT06480552)
- 11 Jul 2024 Phase-I clinical trials in Solid tumours (Monotherapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT06480552)
- 04 Jul 2024 Teva Pharmaceutical plans a phase Ia/Ib trial for Solid tumours (Late-stage disease, Monotherapy, Combination therapy, Metastatic disease, Second-line therapy or greater) in July 2024 (IV) (NCT06480552)